Abcam, ab305907, PE Anti-Paxillin antibody [E228]

Size: 100µL
Rabbit Recombinant Monoclonal Paxillin antibody - conjugated to PE.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:E228,
Isotype:IgG,
Conjugation:PE,
Excitation/Emission:Ex: 480;565nm, Em: 578nm,
Carrier free:No,
Applications:Antibody Labelling, Target Binding AffinitySee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.,
Specificity:The mouse and rat recommendation is based on the WB results. We do not guarantee IHC-P for mouse and rat.

Product details:
conjugated primary antibody
is "made to order" and it is released using a quantitative quality control method that ensures binding affinity and labelling efficiency of the conjugate. Via leveraging the power of the
Lightning-Link® conjugation technology
, Abcam will deliver highly consistent recombinant conjugates in <2 weeks, giving you access to an ever growing portfolio of antibody-label combinations.
For suitable applications and species reactivity, please refer to the unconjugated version of this clone.
How are conjugated primary antibodies validated?
This conjugated primary antibody is released using a quantitative quality control method that evaluates binding affinity post-conjugation and efficiency of antibody labeling.
For suitable applications and species reactivity, please refer to the unconjugated version of this clone.
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.4Preservative: 0.02% Sodium azideConstituents: PBS, 1% BSA, Shipped at conditions-Blue Ice, Appropriate short-term storage duration-1-2 weeks, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Aliquoting information-Upon delivery aliquot, Storage information-Avoid freeze / thaw cycle, Store in the dark

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
Paxillin also known as PXN is a cytoskeletal protein involved in the assembly of focal adhesions. It has a molecular weight of approximately 68 kDa. You will find Paxillin expressed widely in various tissues including the liver colon and lung. Paxillin plays a part in cell motility by interacting with other focal adhesion proteins. It plays a significant mechanical role by serving as a docking site for structural and signaling molecules.
Biological function summary
Paxillin serves key functions in cellular processes such as migration proliferation and survival. It interacts with different proteins including vinculin and talin forming part of a complex at the focal adhesion sites. The phosphorylation state of Paxillin can modulate its interactions and in this way influence the assembly of signaling complexes that control dynamic cellular processes.
Pathways
Paxillin participates in the integrin signaling and MAPK pathways. It operates by linking integrin receptors to the actin cytoskeleton facilitating signal transduction. Paxillin phosphorylation is an important regulatory mechanism within these pathways. In particular its interaction with focal adhesion kinase (FAK) and Src family kinases signifies its role in transmitting signals from the extracellular matrix to the cellular interior which impacts cell behavior and response.
Paxillin has links with osteosarcoma and lung cancer. Deregulation of Paxillin expression or its phosphorylation state contributes to oncogenic transformation and tumor progression. In cancer Paxillin associates with altered activity of proteins such as Src and FAK exacerbating disease states. This relationship highlights Paxillin's potential as a biomarker and therapeutic target in treating related malignancies.